The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
An article from
News roundup
The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
Published Aug. 24, 2026
Getty Images
Why Is Capricor Therapeutics Stock Trading Higher on Monday? - Capricor Therapeutics (NASDAQ:CAPR)
Capricor's Duchenne cell therapy gets PDUFA date extended as FDA reviews new data
Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
Capricor Therapeutics, Inc. Investor Alert - Robbins LLP Reminds CAPR Investors with Significant Losses of the Opportunity to Lead the Class Action Lawsuit Against the Company
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug…
FDA briefing documents question Capricor's deramiocel efficacy in DMD, while the company defends its trial analysis ahead of July…
Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9…
Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks…
Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel…
Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)
